Probabilistic community detection with unknown number of communities J Geng, A Bhattacharya, D Pati Journal of the American Statistical Association, 1-13, 2018 | 82 | 2018 |
Bayesian spatial homogeneity pursuit of functional data: an application to the us income distribution G Hu, J Geng, Y Xue, H Sang Bayesian Analysis 18 (2), 579-605, 2023 | 27 | 2023 |
The MDM2–p53 antagonist brigimadlin (BI 907828) in patients with advanced or metastatic solid tumors: results of a phase Ia, first-in-human, dose-escalation study P LoRusso, N Yamamoto, MR Patel, SA Laurie, TM Bauer, J Geng, ... Cancer Discovery 13 (8), 1802-1813, 2023 | 24 | 2023 |
Bayesian nonparametric nonhomogeneous Poisson process with applications to USGS earthquake data J Geng, W Shi, G Hu Spatial Statistics 41, 100495, 2021 | 19 | 2021 |
Heterogeneity Learning for SIRS model: an Application to the COVID-19 G Hu, J Geng Statistics and Its Interface, 2020 | 16 | 2020 |
A phase I dose-escalation study of the MDM2-p53 antagonist BI 907828 in patients (pts) with advanced solid tumors. P LoRusso, MM Gounder, MR Patel, N Yamamoto, TM Bauer, S Laurie, ... Journal of Clinical Oncology 39 (15_suppl), 3016-3016, 2021 | 11 | 2021 |
A phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist BI 907828 in patients with solid tumors, including advanced/metastatic liposarcoma (LPS). MM Gounder, N Yamamoto, MR Patel, TM Bauer, P Schöffski, R Grempler, ... Journal of Clinical Oncology 40 (16_suppl), 3004-3004, 2022 | 10 | 2022 |
A phase Ia/Ib, dose-escalation/expansion study of BI 907828 in combination with BI 754091 (ezabenlimab) and BI 754111 in patients (pts) with advanced solid tumors. N Yamamoto, N Hafez, AW Tolcher, M Teufel, J Geng, L Svensson, ... Journal of Clinical Oncology 40 (16_suppl), 3095-3095, 2022 | 6 | 2022 |
Efficacy and safety of the MDM2–p53 antagonist BI 907828 in patients with advanced biliary tract cancer: data from two phase Ia/Ib dose-escalation/expansion trials N Yamamoto, AW Tolcher, N Hafez, I Lugowska, R Ramlau, MM Gounder, ... J Clin Oncol 41 (suppl 4), 543, 2023 | 5 | 2023 |
452O A phase I dose-escalation and expansion study evaluating the safety and efficacy of the MDM2–p53 antagonist BI 907828 in patients (pts) with solid tumours P Schoeffski, N Yamamoto, T Bauer, M Patel, MM Gounder, J Geng, ... Annals of Oncology 33, S743, 2022 | 4 | 2022 |
A phase I, open-label, dose-escalation trial of BI 764532, a DLL3/CD3 bispecific antibody, in patients (pts) with small cell lung carcinoma (SCLC) or other neuroendocrine … M Wermke, E Felip, V Gambardella, Y Kuboki, D Morgensztern, ... Journal of Clinical Oncology 39 (15_suppl), TPS8588-TPS8588, 2021 | 4 | 2021 |
Mixture of finite mixtures model for basket trial J Geng, G Hu arXiv preprint arXiv:2011.04135, 2020 | 4 | 2020 |
A phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist BI 907828 in patients (pts) with solid tumors: Safety and efficacy in patients with dedifferentiated … P LoRusso, MM Gounder, N Yamamoto, MR Patel, TM Bauer, J Geng, ... Journal of Clinical Oncology 41 (16_suppl), 11554-11554, 2023 | 3 | 2023 |
A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (MDM2-p53 antagonist) in adult patients with advanced or metastatic solid tumors. CR Chong, TM Bauer, SA Laurie, MR Patel, N Yamamoto, T Davenport, ... Journal of Clinical Oncology 37 (15_suppl), TPS3166-TPS3166, 2019 | 3 | 2019 |
Discovery among binary biomarkers in heterogeneous populations J Geng, EH Slate Statistical Modeling in Biomedical Research: Contemporary Topics and Voices …, 2020 | 2 | 2020 |
Efficacy and Safety of the MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case Series N Yamamoto, A Tolcher, N Hafez, I Lugowska, R Ramlau, T Macarulla, ... OncoTargets and Therapy, 267-280, 2024 | 1 | 2024 |
1548P A phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist BI 907828 in patients (pts) with advanced/metastatic sarcoma M Gounder, MR Patel, N Yamamoto, TM Bauer, S Laurie, A Perez-Pitarch, ... Annals of Oncology 32, S1124-S1125, 2021 | 1 | 2021 |
Bayesian models for capturing heterogeneity in discrete data J Geng The Florida State University, 2017 | 1 | 2017 |
Efficacy and safety of brigimadlin (BI 907828), an MDM2–p53 antagonist, in patients (pts) with advanced biliary tract cancer: Data from two phase Ia/Ib dose-escalation … T Macarulla, N Yamamoto, AW Tolcher, N Hafez, I Lugowska, R Ramlau, ... Journal of Clinical Oncology 42 (3_suppl), 487-487, 2024 | | 2024 |
An exploration of National Weather Service daily forecasts using R Shiny D Roy, G Vaughan, J Hui, J Geng Computational Statistics 38 (3), 1173-1191, 2023 | | 2023 |